Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) for the reporting date of July 31, 2024. The filing addresses a regulatory notice regarding the continued listing of the company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing status and compliance with Nasdaq rules.
Material Changes
- Listing Transfer: Effective August 1, 2024, the company's common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market.
- Compliance Extension: Nasdaq granted an additional 180 calendar days (until January 27, 2025) to regain compliance with the minimum closing bid price requirement (Rule 5550(a)(2)).
- Deficiency: The company failed to maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the bid price and considers available options to resolve the deficiency, including a potential reverse stock split. There is no assurance that the company will regain compliance or avoid delisting. If compliance is not demonstrated by January 27, 2025, the stock will be subject to delisting, at which point the company may appeal to a Nasdaq Hearings Panel.
Investor Verification Checklist
- Verify the current trading status and market tier (Nasdaq Capital Market) of CARA stock.
- Monitor the daily closing bid price to assess progress toward the $1.00 threshold.
- Watch for future announcements regarding a potential reverse stock split.
- Confirm the final compliance deadline of January 27, 2025.